Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 23rd Annual Global Healthcare

Company Overview - Trevi has had a strong year as a single-asset company focused on a drug in the opioid category, specifically a mixed agonist-antagonist subcategory [3] - The drug offers the benefits of opioids, including good efficacy and safety, while minimizing addiction potential [3] - The drug has been unscheduled, allowing for broader access and potential market opportunities [3] Mechanism of Action - The unique mechanism of the drug works both centrally and peripherally, enhancing its therapeutic profile [4]